Related Experiment Video
Updated: Jun 8, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
Published on: November 29, 2024
Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic
Wilfried Dinh1, Mark Lankisch, Werner Nickl
1Institute for Heart and Circulation Research, University Witten/Herdecke, Germany. wilfried.dinh@helios-kliniken.de
Insights
Insulin resistance (IR) is linked to left ventricular diastolic dysfunction (LVDD), a precursor to heart failure. Early screening for IR and glucose metabolism issues can help prevent LVDD development.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Syndrome
Background:
- Left ventricular diastolic dysfunction (LVDD) precedes diabetic cardiomyopathy.
- Insulin resistance (IR) precedes type 2 diabetes mellitus (T2DM) and predicts heart failure (HF).
Purpose of the Study:
- To investigate the relationship between insulin resistance (IR), glucose metabolism abnormalities, and left ventricular diastolic dysfunction (LVDD).
Main Methods:
- 208 patients with normal ejection fraction were studied.
- Insulin resistance (IR) assessed via HOMA-IR; threshold set at 3.217.
- Oral glucose tolerance test (oGTT) used for glucose metabolism assessment; LVDD diagnosed per guidelines.
Main Results:
- 38% of non-diabetic patients had IR.
- LVDD prevalence was 92% in patients with IR versus 72% without IR (p=0.013).
- Higher E/E'av ratio in IR patients (9.8 vs 8.1, p=0.011), independently associated with LVDD (OR 2.1, p=0.001).
Conclusions:
- Insulin resistance (IR) is independently associated with LVDD in patients without overt T2DM.
- Patients with IR and glucose metabolism disorders are a target for preventing heart failure (HF).
- Screening for glucose metabolism disturbances should include diastolic function and IR assessment.
Background:
Left ventricular diastolic dysfunction (LVDD) is considered a precursor of diabetic cardiomyopathy, while insulin resistance (IR) is a precursor of type 2 diabetes mellitus (T2DM) and independently predicts heart failure (HF). We assessed whether IR and abnormalities of the glucose metabolism are related to LVDD.
Methods:
We included 208 patients with normal ejection fraction, 57 (27%) of whom had T2DM before inclusion. In subjects without T2DM, an oral glucose tolerance test (oGTT) was performed. IR was assessed using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). The lower limit of the top quartile of the HOMA-IR distribution (3.217) was chosen as threshold for IR. LVDD was verified according to current guidelines.
Results:
IR was diagnosed in 38 (18%) patients without a history of diabetes. The prevalence of LVDD was 92% in subjects with IR vs. 72% in patients without IR (n = 113), respectively (p = 0.013). In the IR group, the early diastolic mitral inflow velocity (E) in relation to the early diastolic tissue Doppler velocity (averaged from the septal and lateral mitral annulus, E'av) ratio (E/E'av) was significantly higher compared to those without IR (9.8 [8.3-11.5] vs. 8.1 [6.6-11.0], p = 0.011). This finding remains significant when patients with IR and concomitant T2DM based on oGTT results were excluded (E/E'av ratio 9.8 [8.2-11.1)] in IR vs. 7.9 [6.5-10.5] in those without both IR and T2DM, p = 0.014). There were significant differences among patients with and without LVDD regarding the HOMA-IR (1.71 [1.04-3.88] vs. 1.09 [0.43-2.2], p = 0.003). The HOMA-IR was independently associated with LVDD on multivariate logistic regression analysis, a 1-unit increase in HOMA-IR value was associated with an odds ratio for prevalent LVDD of 2.1 (95% CI 1.3-3.1, p = 0.001). Furthermore, the E/E'av ratio increases along the glucose metabolism status from normal glucose metabolism (7.6 [6.2-10.1]) to impaired glucose tolerance (8.8 [7.4-11.0]) and T2DM (10.5 [8.1-13.2]), respectively (p < 0.001).
Conclusions:
Insulin resistance is independently associated with LVDD in subjects without overt T2DM. Patients with IR and glucose metabolism disorders might represent a target population to prevent the development of HF. Screening programs for glucose metabolism disturbances should address the assessment of diastolic function and probably IR.
Related Concept Videos
Heart Failure II: Pathophysiology
Cardiomyopathy II: Dilated Cardiomyopathy
Type II Diabetes II: Pathophysiology
Mitral Regurgitation I: Introduction
Type I Diabetes II: Pathophysiology
Diabetes: Symptoms, Diagnosis, and Complications
